REHOVOT, Israel and JERSEY CITY, New Jersey, November 26 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release third quarter financial results on December 5, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on Friday, December 5.
To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035; international participants may dial 44-20-8196-1998. The access code for the replay is 181543#. The replay will be available until December 12, 2008.
A live audio webcast of the call will also be available on the Investors section of the company's website, http://www.RosettaGenomics.com. An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first microRNA diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.
Contact: Media Investors Ron Kamienchick T: 1-646-509-1893 E: investors@rosettagenomics.com
Contact: Media Investors, Ron Kamienchick, T: 1-646-509-1893, E: investors@rosettagenomics.com
Comments